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A B S T R A C T
Chikungunya is an infection caused by the Chikungunya virus and transmitted by the bite of infected
mosquito. The most common symptoms of Chikungunya virus infection are fever, joint pain or rash.
Chikungunya virus outbreaks had been identiﬁed in countries in Africa, Asia, Europe, and the Indian and
Paciﬁc Oceans. In late 2013, the ﬁrst local transmission of Chikungunya virus in the Americas was
identiﬁed in Caribbean countries and territories. Chikungunya virus disease became a nationally
notiﬁable condition in 2015. There is a threat that Chikungunya will continue to spread to new areas in
the Americas.
We describe 5 patients who presented to our hospital with Chikungunya infection, shortly after
returning from endemic areas. Fever and travel history to endemic areas were documented in all of our
cases. Skin rash, arthralgia and contact history were also reported by these patients. Persons with
suspected Chikungunya infection should be counseled to avoid mosquito bites during illness to decrease
the risk of local transmission. The transmitting mosquitos are present in the US, and limiting the viral
spread is essential. In this report, we describe the clinical presentation, risk factors and laboratory tests of
each patient, and attempt to ensure awareness on the risk of potential spread of the disease.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chikungunya, originally endemic to West Africa, is an arthro-
pod-borne virus (arbovirus). The virus is closely related to
o’nyong’nyong virus. The disease was ﬁrst described by Marion
Robinson and W.H.R. Lumsden in 1955, following an outbreak in
1952 on the Makonde Plateau, Tanzania. The disease Chikungunya
disease manifests as acute onset of fever, muscle and joint pains,
and frequently nonspeciﬁc maculopapular rash [1]. The case
fatality ratio is about 1 per 1000, with most deaths occurring
among newborns, the elderly, and the debilitated [1].
Since 2004, Chikungunya has spread broadly, causing massive
and sustained outbreaks in Asia and Africa [2]. In 2013,
Chikungunya virus infections have spread widely in the Americas
[3]. As of December 2014, local transmission had been identiﬁed in
41 countries or territories in the Caribbean, Central America, South
America, or North America. A total of 1,012,347 suspected and* Corresponding author at: Department of Medicine, Nassau University Medical
Center: an afﬁliation of North Shore Long Island Jewish Health Care System, East
Meadow, NY, USA. Tel.: +1 5715054640.
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4.0/).22,579 laboratory-conﬁrmed Chikungunya cases had been
reported from these areas [4].
The virus is transmitted by the bites of infected mosquitos Aedes
aegypti (Yellow fever mosquito) and Aedes albopictus (Asian tiger
mosquito), both present in the Americas. Chikungunya virus likely
will continue to spread to new areas in the Americas through
infected people and mosquitoes. Increasing number of cases has
been identiﬁed in travelers returning from outbreak areas
[5]. Therefore this case report reviews 5 cases of Chikungunya,
who presented to our hospital shortly after returning from abroad,
in attempt to ensure awareness on the risk of potential spread of
the disease.
Case presentation
Case 1
A 36 year old female presented to the ER on October 28th,
2014 with subjective fever and generalized bone, joint and muscle
pain of 8 days. The patient recently returned from El Salvador
(8 days ago). She had a rash over both lower extremities which has
now resolved. She gave a history of multiple sick contacts with
people who had similar symptoms. Patient had a temperature ofe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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and started with antibiotics and supportive care. She tested
positive for Chikungunya ELISA test. All other investigations were
negative. The patient became asymptomatic in few days and was
discharged. The patient was followed in the clinic the following
month, at which time she did not have any fever, joint pain or rash.
Case 2
A 50 year old male presented on July 26th, 2014 with fever of 2–
3 days after returning from Haiti. He developed rash on the feet
which spread toward the trunk. The patient complained of chills,
arthralgia and myalgia. On the day of admission, he developed
bullous lesions on his feet. The patient had a sick contact
(girlfriend) in Haiti who also had fever. The patient had
maculopapular rash over all the four extremities sparing the
palms and soles with intact bullous lesions on both feet. The
patient was admitted for further work up, started on antibiotics
and IV hydration. Basic Laboratory workup was within normal
limits. The patient’s symptoms improved during his stay in the
hospital and he was discharged home. The patient’s serology came
back positive for Chikungunya antibodies.
Case 3
A 65 year old Haitian female presented to the ER on July 31st,
2014 with generalized muscle aches, joint pain, and neck pain. Her
symptoms had been present for few days. The patient had fever
while in Haiti but this resolved before returning to the U.S. The
patient denied any other complaint. Physical exam was unre-
markable except for tender limb muscles and paraspinal muscles
of neck. There were no meningeal signs. Viral syndrome was
suspected, so supportive management was started with ﬂuids and
analgesics. Serology sent for Chikungunya was positive. The
patient improved clinically while in the hospital and discharged
symptoms free.
Case 4
A 14 year old female patient, previously healthy, admitted with
abnormal behavior of 1 day duration on August 28th, 2014. The
patient had traveled to Dominican Republic and returned to the US
after staying there for 7 weeks. She developed acute behavioral
changes: disorganized slow speech and abnormal thoughts. She
had fever and chills. Her parents gave history of diffuse skin rash
(red dots) on chest, back, abdomen, arms and legs. The patient had
a history of contact with Chikungunya patients (her father and
sister). On admission, she was conscious but with slow responses
and disorganized speech. The remaining neurology exam was
unremarkable. The patient was started on antiviral for possible
viral encephalopathy. Investigations including toxicology, viral/
bacterial cultures, spinal tap, EEG and CT/MRI of brain were
negative. The patient tested positive for Chikungunya and Dengue
antibodies. The patient improved clinically while in the hospital
and was discharged with out-patient appointment.
Case 5
A 45 year old male presented to the ER on October 3rd,
2014 complaining of fever and rash. The patient came from El
Salvador 5 days ago and started experiencing fevers that persisted
for 3 days after arrival. Tmax was noted to be 102.2 8F. Three days
after arrival, the patient developed rash on both upper and lower
extremities, which then rapidly spread to the rest of his body. The
patient also experienced arthralgia and myalgia. He reported
multiple mosquito bites. On admission, patient was noted to havediffuse maculopapular erythematous rash on the trunk and all
extremities sparing palms and soles. The patient was started on
supportive treatment. The patient’s symptoms improved and he
remained afebrile throughout his hospital course. Serum test for
Chikungunya and Dengue were not sent. Based on his fever,
arthralgia, rash and his recent visit to epidemic area, we strongly
believe that this was a case of Chikungunya fever. The patient
meets the clinical and epidemiological criteria for a probable case
of Chikungunya infection [3].
Discussion
Chikungunya infection presents with abrupt febrile episodes
and malaise, following an incubation period of 2–4 days [6]. All our
patients presented with subjective or recorded fever, indicating
that fever is the most prominent presentation of the disease.
Polyarthralgia begins few days after the onset of fever, and
commonly involves multiple joints symmetrically [7]. Four of our
cases had associated arthralgia involving multiple joints. These
resolved over time with no long term complications.
Skin involvement such as macular or maculopapular rash
(starts usually 3 days after the onset of illness and lasts 3–7 days).
Rash has been reported in 40–75% of patients [8]. This usually
starts on the limbs and trunk, and may be patchy or diffuse. Two of
the cases had history of skin rash but not noted on admission,
signifying late presentation of these cases. Two of the patients had
skin lesion on admission which was maculopapular rash over the
extremities indicating typical presentation for Chikungunya.
Recent Chikungunya infection has been associated with
neurological complications. Encephalitis is the most common
neurologic complication [9]. There are no residual sequelae. One of
the cases presented with altered mental status, for which work up
was negative except for Chikungunya and Dengue serology.
Although an atypical presentation, Chikungunya should be
considered as one of the possibilities for patients presenting with
altered mental status.
Chikungunya, being a viral infection, causes leucopenia or
lymphopenia. Only one of our cases presented with low WBC
count. The same patient also had thrombocytopenia, which is
unusual for Chikungunya (Table 1). Travel history to endemic areas
of the Caribbean and Latin America was documented in all of our
cases. Therefore clinicians should be aware of potential Chikun-
gunya infection in travelers returning from endemic or outbreak
areas, and presenting with fever.
It is also important to consider co-infections with Dengue.
One of our cases had co-infection with Chikungunya and Dengue.
Both viruses are transmitted by same Aedes genus and both
can occur in many regions due to climatic changes. The clinical
presentation of both arthropod borne diseases are similar
[10]. Differentiating between the two is a clinical challenge.
The distinguishing feature is joint pain which is prominent in
Chikungunya infection.
Serology is the primary diagnostic tool. Immunoglobulin M
(IgM) anti-Chikungunya virus antibiodies can be detected starting
about 5 days following the onset of symptoms. IgM usually persists
for several weeks to 3 months, whereas Immunoglobulin G (IgG)
antibodies begin to appear about 2 weeks following the onset of
symptoms and can persist for years [13]. Four cases tested positive
to both Chikungunya antibodies IgM and IgG with higher titer for
IgM indicating a recent infection.
Treatment is mainly supportive. Anti-inﬂammatory and anal-
gesic agents are used to relieve symptoms. There are no studies
conﬁrming the efﬁcacy of antiviral agents in human infection,
although ribavirin and interferon-alpha appear to have some in
vitro activity against viral replication [14]. Our patients were
started empirically on antibiotics for possible infections but the
Table 1
Characteristics of 5 cases based on clinical presentation and risk factors.
Characteristics Case 1 Case 2 Case 3 Case 4 Case 5
Fever + + + + +
Joint pain + + + S +
Skin rash + +  + +
Travel history to endemic area El Salvador Haiti Haiti Dominican Republic El Salvador
Contact history + +  + 
White blood cells (cells/mm3) 3800
(N: 73%, L: 10%)
6630
(N:84% L:11%)
6630
(N: 55%, L: 37%)
13,720
(N: 78%, L: 15%)
6730
(N: 79%, L:9%)
Platelet (cells/mm3) 91,000 192,000 319,000 345,000 300,000
Chikungunya antibodies (titers) IgM (1:1280)
IgG (1:640)
IgM (1:640)
IgG (1:640)
IgM (1:1280)
IgG (1:320)
IgM (1:640)
IgG (1:1280)
unavailable
Co infection with Chikungunya and Dengue   unknown + unknown
This table illustrates the similarity and difference among the cases, based on different characteristics. These characteristics were extracted from the WHO proposed case
deﬁnition of Chikungunya including the different criteria for diagnosis.
(+) indicates that the speciﬁc character is present. () indicates that the speciﬁc character is absent. (unknown) indicates that there is no evidence available to document as
either.
N: neutrophils (in percent) and L: lymphocytes (in percent).
ELISA test for Chikungunya antibodies detected IgM (Immunoglobulin M) and IgG (Immunoglobulin G). Reference range is negative for IgM and IgG. In the table, the
antibodies are reported in titers.
Case 2 and 3 were screened for Malaria and results were negative.
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supportive treatment to which they responded. This experience
highlights the need for more awareness about the disease and
avoiding unnecessary interventions.
Some risk exists that Chikungunya might be introduced into
previously non-endemic areas by travelers with viremia, leading to
local transmission of the virus, especially in tropical or subtropical
areas of the United States [11]. Persons with suspected Chikungu-
nya infection should be counseled to avoid mosquito bites during
the ﬁrst week of illness to decrease the risk of local transmission
[5]. We would like to emphasize on the potentials of local
transmission, as the mosquito (A. albopictus) is reported to be
found in central and eastern regions of the U.S., including New York
[12]. The likely danger of spreading the mosquitoes from endemic
area by means of aircraft should also be investigated, as this was a
recognized mechanism for ‘‘airport malaria’’ cases [15].
Chikungunya fever is a mosquito-borne infection for which no
licensed vaccine is currently available [16]. Therefore, prevention
recommendations for travelers to endemic areas should empha-
size on mosquito repellent and avoidance measures like mosquito
nets, long pants and sleeves. It is important for providers to give
preventive information to their patients traveling to endemic
areas.
Conclusion
Chikungunya disease should be considered as one of the
differential diagnoses when a traveler returns from an endemic
area with fever, rash, arthralgia, or a combination of these
symptoms. The increased frequency of individuals traveling
around the world, increased incidence of the disease and the
presence of mosquitos in the Americas is a major concern for
possible outbreaks in the western hemisphere. Clinicians and
public health ofﬁcials should be cautious of the possibility of local
transmission of Chikungunya virus. The importance of educating
the public and bringing awareness to the health care providers
should be emphasized.
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